• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Soligenix

edit

Soligenix, Inc. is a late-stage research and development biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatment and serious gastrointestinal diseases where there remains an unmet medical need, as well as developing biodefense vaccines and therapeutics. The Company maintains two business segments: BioTherapeutics and BioDefense. Its BioTherapeutics business segment focuses to develop oral beclomethasone dipropionate (orBec or oral BDP) and other biotherapeutic products, including LPMTM Leuprolide. Its BioDefense business segment focuses to convert its ricin toxin vaccine and radiation injury program from early stage development to advanced development and manufacturing.

Recent Milestones

edit

• 
  Soligenix received $5.16M in Venture Round funding. (6/16/10)
  Posted 7/7/10 at 1:18am via dorbiopharma.com
• 
  Soligenix added Christopher J. Schaber as President and CEO.
  Posted 7/7/10 at 1:18am
• 
  Went public with stock symbol OTC:SNGX.
  Posted 7/7/10 at 1:18am
• 
  Soligenix added Evan Myrianthopoulos as CFO.
  Posted 7/7/10 at 1:18am

Videos

Screenshots

edit

Above: Home Page
Uploaded: 7/7/10

Stock Price

Sources

1. Soligenix Announces Private Equity Financing of $5.16 Million with its Partner Sigma-Tau and other Institutional Investors (dorbiopharma.com) [edit]